WS #11999
Holding: newest synthesis is 129d 6h old
Erasca announces $500M common stock offering and updated Phase 1 data for ERAS-0015 with 57% uORR in pancreatic cancer; plans registration-enabling trials.
Erasca $500M Stock Offering and Clinical Data
Erasca announces $500M common stock offering and updated Phase 1 data for ERAS-0015 with 57% uORR in pancreatic cancer; plans registration-enabling trials.